RE: RE: RE: RE: RE: RE: Albiglutide Scott, this is far from impossible. The article posted earlier makes me understand that GSK want to get back some chunk of the market in the diabetic field.
They could do like Celgene, and "secure" the receipe in the diabetic field with the specific ligand used, as GSK could push further the R&D on other diabete's drug. I do remember having read something about a once a month injection in future project.